Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?
about
Update on schizophrenia and bipolar disorder: focus on cariprazineThe Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic ReviewAripiprazole: from pharmacological profile to clinical useTargeting G protein coupled receptor-related pathways as emerging molecular therapiesDopamine D1 receptor signaling: does GαQ-phospholipase C actually play a role?Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor AntagonismDopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and FutureUnique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3β Signalling Pathways in RatsSKF-83959 is not a highly-biased functionally selective D1 dopamine receptor ligand with activity at phospholipase CSerotonergic modulation of conditioned fear.Reward processing in autism: a thematic series.Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial.The First Negative Allosteric Modulator for Dopamine D2 and D3 Receptors, SB269652 May Lead to a New Generation of Antipsychotic DrugsAntioxidant Treatment with N-acetyl Cysteine Prevents the Development of Cognitive and Social Behavioral Deficits that Result from Perinatal Ketamine TreatmentClassics in Chemical Neuroscience: Aripiprazole.Potential molecular and cellular mechanism of psychotropic drugsComparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.Noradrenaline-induced release of newly-synthesized accumbal dopamine: differential role of alpha- and beta-adrenoceptors.Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy.Discovery of GPCR ligands for probing signal transduction pathways.New functional activity of aripiprazole revealed: Robust antagonism of D2 dopamine receptor-stimulated Gβγ signalingPharmGKB summary: dopamine receptor D2Treatment implications of predominant polarity and the polarity index: a comprehensive review.Elucidation of G-protein and β-arrestin functional selectivity at the dopamine D2 receptorAn update of safety of clinically used atypical antipsychotics.Estimating multivariate similarity between neuroimaging datasets with sparse canonical correlation analysis: an application to perfusion imaging.Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists.Dispensable, redundant, complementary, and cooperative roles of dopamine, octopamine, and serotonin in Drosophila melanogaster.Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse.Aripiprazole and Haloperidol Activate GSK3β-Dependent Signalling Pathway Differentially in Various Brain Regions of Rats.Waterborne aripiprazole blunts the stress response in zebrafish.Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models.Comparison of oscillatory activity in subthalamic nucleus in Parkinson's disease and dystonia.Pharmacokinetics and metabolism update for some recent antipsychotics.Serotonin 2A receptor antagonists for treatment of schizophrenia.Atypical antipsychotic-induced weight gain: insights into mechanisms of action.Pain management in neurocritical care.Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome.Quinoline- and isoquinoline-sulfonamide analogs of aripiprazole: novel antipsychotic agents?Drug repurposing and emerging adjunctive treatments for schizophrenia.
P2860
Q26741533-DD9A5223-3FC4-4C2F-86C1-6979D462BC40Q26748677-092329B2-F684-4AD4-BF83-559149B5C888Q26778312-68F4AA12-35C4-4354-AC1E-D6EF9BBFC276Q26829964-95E3B392-C8B8-4079-9CAA-5BA1B2EBA28DQ26864383-9E495263-0322-4D98-9A7E-8EE64DB251EBQ28084069-E4B22CA9-197B-482F-91EA-EAC2603174C0Q28394341-3A58E36E-E33D-4A01-84BC-B3BC41422B48Q28546441-C3D80586-8E01-49FF-8520-261AD84684ECQ30400003-C6608ACD-EF53-4166-BB8C-04648C3AF103Q30446862-1B3B333D-03B1-49DD-B9F5-A86FF4A5D90FQ30462673-EB7A6632-2EB9-4F41-85A8-85BFAF43EBBBQ30490025-6BBC8ECB-68AD-4046-A477-7EF27A2F6082Q33707895-20B3A380-71C6-4B05-B740-16AFA17BA61EQ33766147-CAB9A063-0DBA-456E-889C-5C6EACB19B85Q33866125-AA842302-7D5B-4AF6-88E9-5DCEF5998788Q34129880-38314435-CDB5-47FE-9791-3BBBEAC7800BQ34169978-B5379746-D975-4C27-B15D-F0038DA5A009Q34171671-2F543948-C9F0-486A-B015-CC3562C4E99AQ34227284-6D121EBF-5A1D-43DC-ADC6-6B67CEA8BC1FQ34582707-583814F9-8DEF-43EA-9F31-F99AEDE80584Q34772251-84C9CC17-A394-46B2-BACB-F2CF59480137Q34970259-A8161720-C806-4BAF-9F3E-B4D72601918EQ35203680-DEA521F9-71C5-47FB-8406-0744BC23F14DQ35698989-B2F3253B-9338-423B-8564-056B5445841AQ36062184-825041D1-5C62-461E-8979-DE71C082E965Q36154333-635B26F7-C2CE-49BA-BD41-FC0681434E9BQ36237653-45BCD79F-2F0F-4838-B8D1-5DB7E9073D0DQ36480380-2EC3C0AC-B988-42AF-8BE1-6E84FEB21963Q36609334-5B3831F7-A83E-4931-9D12-D9C3B6B80035Q36846918-872B47E1-0CCF-4B89-95C1-9A8D733FA5C4Q37428054-499996FA-7C86-4E2B-A870-3150010A31E5Q37624658-3DEA05DA-AF7B-4734-9F4C-316E8DF8BE64Q37660411-F363BC63-E045-4D45-8F35-01EDFFC6BE77Q37863118-ACA0206F-9060-4449-AC92-4D2A113738FFQ37899193-D4E2D9C1-B011-45F6-BAB4-09ED213504DDQ37963571-9E4C7EC6-746B-4143-BB6C-400BFE4B86AAQ38124745-C327AA77-0E88-4D8F-8C60-F90E75B1D1A9Q38163049-3BCEA212-F66C-43B7-B132-C713EFFD4597Q38172958-EC168D08-AC36-48AB-A9FC-9494C60B744EQ38417631-C95D6810-CD7A-4DF9-94A4-E7962C288741
P2860
Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?
@ast
Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?
@en
type
label
Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?
@ast
Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?
@en
prefLabel
Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?
@ast
Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?
@en
P2860
P1476
Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?
@en
P2093
Vishakantha Murthy
P2860
P304
P356
10.2174/138161210790361461
P577
2010-01-01T00:00:00Z